RxDoctor Payments Data

George Cater, MD

Cardiovascular Disease · Pittsburgh, PANPI 1578805644

Payments from drug & device makers

$1,441in general payments, 2019–2025

Across 62 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$309
  • Johnson & Johnson$228
  • Pfizer$205
  • E.r. Squibb & Sons, L.L.C.$153
  • Edwards Lifesciences$153
  • AstraZeneca$75
  • plus $318 from 11 others

What the payments were for

  • Food & beverage$1,441100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,441 in reported general payments places this provider in the 45th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$87,199
Medicare patients
1,123
Services billed
1,902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$106,538
EntrestoSacubitril/Valsartan34$31,524
Repatha SureclickEvolocumab19$17,827
Metoprolol Succinate177$2,317
Valsartan31$1,640
Bumetanide39$1,513
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$1,203
Atorvastatin Calcium110$1,155
Spironolactone113$767
Rosuvastatin Calcium55$638
Furosemide125$618
Isosorbide Mononitrate ErIsosorbide Mononitrate44$495
Carvedilol62$478
Bisoprolol Fumarate13$375
ClopidogrelClopidogrel Bisulfate32$368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$205$106,538112 claims
NovartisEntresto$27$31,52434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →